Overview

Ribociclib and Letrozole Treatment in Ovarian Cancer

Status:
Recruiting
Trial end date:
2021-12-31
Target enrollment:
Participant gender:
Summary
The study evaluates the response to treatment with Ribociclib and Letrozole in patients with low grade serous cancer of the ovary, fallopian tube or peritoneum.
Phase:
Phase 2
Details
Lead Sponsor:
Gynecologic Oncology Group
Collaborator:
Novartis
Treatments:
Letrozole